Reduction in mortality and target-lesion revascularisation at 2 years: A comparison between drug-eluting stents and conventional bare-metal stents in the "real world"

International Journal of Cardiology

Volumn 132, Issue 3, 2009, Pages 398-404

  Alahmar, Albert E ^a   Grayson, Antony D ^a   Andron, Mohammed ^a   Egred, Mohaned ^a   Roberts, Elved D ^a   Patel, Bilal ^a   Moore, Roger K G ^a   Albouaini, Khaled ^a   Jackson, Mark ^a   Perry, Raphael A ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

All cause mortality; Drug eluting stent; Percutaneous coronary intervention; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RETREATMENT; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 60649091678     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.03.001     Document Type: Article

References (32)

1. Kastrati A., Elezi S., Dirschinger J., Hadamitzky M., Neumann F.J., and Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 83 (1999) 1617-1622
2. Elezi S., Kastrati A., Pache J., et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32 (1998) 1866-1873
3. Elezi S., Kastrati A., Neumann F.J., Hadamitzky M., Dirschinger J., and Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 98 (1998) 1875-1880
4. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
5. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
6. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
7. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
8. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
9. Regar E., Serruys P.W., Morice M.C., et al. Angiographic findings of the multicenter Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106 (2002) 1949-1956
10. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
11. Dawkins K.D., Grube E., Guagliumi G., et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112 (2005) 3306-3313
12. Roiron C., Sanchez P., Bouzamondo A., Lechat P., and Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 92 (2006) 641-649
13. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real world': the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
14. Williams D.O., Abott J.D., and Kip K.E. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. Report of the DEScover Registry. Circulation vol. 114 (2006) 2154-2162
15. Saia F., Piovaccari G., Manari A., et al. Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: results from a large multicenter registry. J Am Coll Cardiol 48 (2006) 1312-1318
16. Pfisterer M., Burnner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
17. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
18. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
19. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
20. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
21. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 547-581
22. Blackstone E. Comparing apples and oranges. J Thorac Cardiovasc Surg 123 (2002) 8-15
23. Parsons L.S. Reducing bias in a propensity score match-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Long Beach, CA (2001), SAS Institute Inc, Cary, NC
24. Guagliumi G., Farb A., Musumeci G., et al. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 107 (2003) 1340-1341
25. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
26. Feres F., Costa Jr. J.R., and Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 68 (2006) 83-88
27. Schampaert E., Moses J.W., Schofer J., et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
28. Kelbaek H., Thuesen L., Helqvist S., et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 47 (2006) 449-455
29. Ruygork P.N., Melkert R., Morel M.A., et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol 34 (1999) 1507-1511
30. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36
31. Weisz G., Leon M.B., Holmes Jr. D.R., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47 (2006) 1350-1355
32. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxeleluting stents in de novo coronary artery lesions. The REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904